(Q45413909)

14 December 2017

A peptide-based inhibitor for prevention of B cell hyperproliferation induced by Epstein-Barr virus (English)

1 reference

14 December 2017

0 references

6

Erle S Robertson

1 reference

14 December 2017

Jason S Knight

1

1 reference

14 December 2017

Ke Lan

2

1 reference

14 December 2017

Bharat Bajaj

3

1 reference

14 December 2017

Nikhil Sharma

4

1 reference

14 December 2017

Donald E Tsai

5

1 reference

14 December 2017

language of work or name

English

0 references

publication date

31 July 2006

1 reference

14 December 2017

1 reference

14 December 2017

354

1 reference

14 December 2017

207-214

1 reference

14 December 2017

1

1 reference

SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene

14 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

Protein transduction technology offers novel therapeutic approach for brain ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

Arginine-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

"Translocatory proteins" and "protein transduction domains": a critical analysis of their biological effects and the underlying mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

Epstein-Barr virus-recent advances

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

Epstein-Barr virus: exploiting the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

Epstein-Barr virus superinduces a new human b cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

Cellular targets for transformation by the adenovirus E1A proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.034

10.1016/J.VIROL.2006.06.034

7 January 2021

Identifiers

DOI

1 reference

14 December 2017

1 reference